View and listen to webcast of June 3 Pfizer analyst and investor meeting at ASCO
22 May 2012 | By Pfizer
View webcast of a presentation by Pfizer’s oncology leadership team...
List view / Grid view
22 May 2012 | By Pfizer
View webcast of a presentation by Pfizer’s oncology leadership team...
18 May 2012 | By Pfizer
Results of studies on Lyrica® announced...
15 May 2012 | By Pfizer
Pfizer Inc announced that the Phase 3 INTORSECT study...
14 May 2012 | By Pfizer
New data will be presented on targeted cancer treatments from the Pfizer Oncology portfolio across three key therapeutic categories...
14 May 2012 | By University of Dundee
The consortium includes six companies & will provide core support of £14.4 million...
10 May 2012 | By Pfizer
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with David Simmons...
9 May 2012 | By Pfizer
“We are pleased with the Committee’s positive evaluation..."
7 May 2012 | By Pfizer
Pfizer announced new data presented at the 165th Annual Meeting of the APA...
4 May 2012 | By Pfizer
Pfizer has stopped a Phase 3 clinical trial of Lyrica in patients with neuropathic pain...
4 May 2012 | By Pfizer
Pfizer announced that a Phase 3 randomized withdrawal design study for Lyrica in patients...
1 May 2012 | By Pfizer
The U.S. FDA has approved ELELYSO™...
18 March 2012 | By Pfizer
Experts on ageing highlight importance of health as driver of economic growth...
12 March 2012 | By Pfizer
Data from a Phase 3 study of Prevnar 13® met all study endpoints...
12 March 2012 | By Pfizer
Biocon and Pfizer have announced the conclusion of their alliance...
29 February 2012 | By Pfizer
The U.S. FDA has extended the action date by three months for the NDA for Eliquis® (apixaban)...